Maria-teresa T. Cedena
Madrid, MD, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 61 publications
Impact of 1q vulnerabilities in patients treated with anti-CD38 monoclonal antibodies.
Journal: Frontiers in oncology
Published: December 01, 2025
Immune biomarkers of increased infection risk in multiple myeloma.
Journal: Blood
Published: September 22, 2025
Real-world evidence of measurable residual disease assessment in multiple myeloma.
Journal: Blood advances
Published: September 18, 2025
The Potential of the Gut Microbiota and Butyrate to Enhance CAR T-cell Therapy in Non-Hodgkin Lymphoma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 06, 2025
Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.
Journal: Blood cancer discovery
Published: March 28, 2025
Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers.
Journal: Blood cancer discovery
Published: March 28, 2025
Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma.
Journal: Nature reviews. Clinical oncology
Published: March 19, 2025
Induction therapy with bortezomib, melphalan, and prednisone followed by lenalidomide and dexamethasone versus carfilzomib, lenalidomide, and dexamethasone with or without daratumumab in older, fit patients with newly diagnosed multiple myeloma (GEM-2017FIT): a phase 3, open-label, multicentre, randomised clinical trial.
Journal: The Lancet. Haematology
Published: January 22, 2025
Last Updated: 09/26/2026